Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Merck’s bet on an antibody-drug conjugate developed in China has paid off in a major Phase 3 lung cancer study, where sacituzumab tirumotecan paired with Keytruda sharply outperformed Keytruda alone in a subset of lung cancer patients.
Also, the NIH is down another leader, and Sam Altman-backed longevity startup Retro Biosciences raises more funds.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
